HEPA
Hepion Pharmaceuticals, Inc.0.0700
-0.0100-12.5%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
813.42KP/E (TTM)
-Basic EPS (TTM)
-9.05Dividend Yield
0%Recent Filings
10-K
FY2025 results
Hepion Pharmaceuticals posted an $8.3M net loss for FY2025 ended December 31, 2025, far better than 2024's $13.2M loss, as R&D crashed 96% to $0.4M after winding down its rencofilstat liver drug trial and selling related assets to Panetta for nominal cash. G&A fell 44% to $3.3M amid headcount cuts to two employees; a $0.4M impairment hit New Day diagnostic licenses. No Q4/annual revenue yet from CE-marked celiac/H. pylori tests, but $9M January 2025 offering boosted cash to $1.8M. Warrant exercises swelled shares to 11.6M. Cash burn slowed, yet going concern doubts persist without funding. Delisting to OTCQB risks liquidity.
8-K
In-licenses ctRNA HCC assay
Hepion Pharmaceuticals in-licensed a novel ctRNA biomarker assay from Cirna Diagnostics on February 25, 2026, for early HCC detection in high-risk cirrhosis patients. The deal includes a $50,000 upfront, up to $2.35M in development milestones, up to $4.5M in sales milestones, and low single-digit royalties. This bolsters Hepion's liquid biopsy pipeline alongside its mSEPT9 assay. Commercialization pathways target CLIA labs and pharma partnerships.
8-K
Hepion names new CEO
Hepion Pharmaceuticals appointed Dr. Kaouthar Lbiati as CEO effective January 8, 2026, under an employment agreement approved January 13 with $350,000 base salary—$50,000 deferred until $3M equity financing—and 35% target bonus. Severance covers six months' pay without cause; equity fully accelerates on termination or change of control over $5M enterprise value, where she earns 3% bonus. New leadership locks in retention amid funding needs.
10-Q
Q3 FY2025 results
Hepion Pharmaceuticals narrowed its Q3 operating loss to $0.5M from $4.5M a year ago, while nine-month net loss hit $7.6M versus $11.6M prior year, thanks to slashed R&D after winding down its liver drug trial. Cash climbed to $2.3M on $9M equity raise that cleared $2.9M notes, leaving $0.2M short-term debt; operations burned $2.9M YTD. License for EU-eligible diagnostics fully impaired at $0.4M due to delayed cash flows. Warrants swung favorably by $47K. Cash won't last. Delisting shadows liquidity.
10-Q
Q2 FY2025 results
Hepion Pharmaceuticals narrowed its Q2 operating loss to $1.7 million from $8.5 million a year earlier, thanks to slashed R&D spending after winding down its liver drug trial, though a $0.4 million asset impairment hit from a new diagnostics license deal tempered gains. Net loss eased to $1.0 million, or $0.09 per share, versus $3.9 million, or $34.00 per share, with the EPS swing reflecting a 98-fold jump in diluted shares to 11.3 million from warrant conversions—no anti-dilution flagged. Cash climbed to $2.9 million on $9.0 million from a January equity raise, which cleared a $2.9 million note, leaving $0.4 million in short-term debt for insurance; free cash flow not disclosed in the 10-Q. The May license for EU-eligible celiac, respiratory, and H. pylori tests cost $0.8 million total but got fully impaired over dim near-term cash flow prospects. Warrants pose a key risk, their fair value swings hammering earnings.
AVIR
Atea Pharmaceuticals, Inc.
3.22+0.07
CANF
Can-Fite Biopharma Ltd Sponsore
0.29+0.02
ENTA
Enanta Pharmaceuticals, Inc.
14.85-0.02
INDP
Indaptus Therapeutics, Inc.
2.21-0.10
INO
Inovio Pharmaceuticals, Inc.
2.32+0.06
PMVP
PMV Pharmaceuticals, Inc.
1.18-0.02
PPCB
Propanc Biopharma, Inc.
0.73-0.03
RXRX
Recursion Pharmaceuticals, Inc.
4.20+0.00
TPST
Tempest Therapeutics, Inc.
2.91-0.03
VIR
Vir Biotechnology, Inc.
6.48-0.24